Current Report Filing (8-k)
January 09 2017 - 8:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): January 9, 2017
EPIZYME, INC.
(Exact
Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
001-35945
|
|
26-1349956
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
400 Technology Square, Cambridge, Massachusetts
|
|
02139
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(617) 229-5872
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Item 7.01
|
Regulation FD Disclosure.
|
Epizyme, Inc. (the Company) intends to present a company
overview at the 35th Annual J.P. Morgan Healthcare Conference on January 9, 2017. The slide deck to be used at such presentation is being furnished as Exhibit 99.1 to this Current Report
on Form 8-K.
The information responsive to Item 7.01 of this Form
8-K,
including Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) The following exhibits are included in this report:
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Company Slide Deck as of January 9, 2017
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
EPIZYME, INC.
|
|
|
|
Date: January 9, 2017
|
|
By:
|
|
/s/ Robert B. Bazemore
|
|
|
Name:
|
|
Robert B. Bazemore
|
|
|
Title:
|
|
President and Chief Executive Officer
|
EXHIBIT INDEX
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Company Slide Deck as of January 9, 2017
|
Epizyme (NASDAQ:EPZM)
Historical Stock Chart
From Apr 2024 to May 2024
Epizyme (NASDAQ:EPZM)
Historical Stock Chart
From May 2023 to May 2024